Briggs, Andrew H.
Andrew H Briggs researcher
Briggs, A H
Briggs, Andrew Harvey
VIAF ID: 46522196 (Personal)
Permalink: http://viaf.org/viaf/46522196
Preferred Forms
- 100 0 _ ‡a Andrew H Briggs ‡c researcher
- 100 1 _ ‡a Briggs, A H
-
-
- 100 1 _ ‡a Briggs, Andrew H.
-
-
- 100 1 _ ‡a Briggs, Andrew H.
- 100 1 _ ‡a Briggs, Andrew Harvey
4xx's: Alternate Name Forms (8)
Works
Title | Sources |
---|---|
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists | |
Decision modelling for health economic evaluation | |
Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial | |
Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. | |
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model | |
Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT | |
Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support | |
Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. | |
Editorial | |
The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. | |
Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. | |
EQ-5D-5L: Smaller steps but a major step change? | |
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations | |
Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19 | |
Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. | |
Evaluation of health in pregnancy grants in Scotland: a protocol for a natural experiment. | |
The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts. | |
Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial | |
The "hazards" of extrapolating survival curves. | |
Health impacts of environmental and social interventions designed to increase deprived communities’ access to urban woodlands: a mixed-methods study | |
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial | |
Health technology assessment in the cost-disutility plane. | |
Hospital expenditure at the end-of-life: what are the impacts of health status and health risks? | |
How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. | |
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. | |
Inhaler competence in asthma: common errors, barriers to use and recommended solutions. | |
Integrated care pathways for airway diseases (AIRWAYS-ICPs). | |
International comparison of comparative effectiveness research in five jurisdictions: insights for the US | |
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. | |
ISPOR-SMDM Task Force’s Recommendations for Good Modeling Practices—Reply to Letter to the Editor by Corro Ramos | |
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study | |
Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: a longitudinal cohort study and economic evaluation. | |
MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. | |
Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. | |
Mobile phone use for contacting emergency services in life-threatening circumstances. | |
Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. | |
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6 | |
Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma | |
Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. | |
Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). | |
Oral versus Intravenous Antibiotics for Bone and Joint Infection | |
Outcome measurement in economic evaluations of public health interventions: a role for the capability approach? | |
A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). | |
PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. | |
A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. | |
Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. | |
Population ageing and healthcare expenditure projections: new evidence from a time to death approach | |
Power and sample size for cost-effectiveness analysis: fFN neonatal screening. | |
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. | |
Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value | |
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models | |
Prognosis Research Strategy (PROGRESS) 2: prognostic factor research | |
The progressivity of health-care financing in Kenya. | |
Projecting long-term graft and patient survival after transplantation. | |
A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial | |
Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report | |
Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. | |
Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration | |
Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. | |
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) | |
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer | |
The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. | |
Statistical analysis of cost-effectiveness data, c2006: | |
A systematic review of continuous performance task research in children prenatally exposed to alcohol. | |
Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. | |
Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981 to 2009 | |
Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure | |
Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. | |
Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial | |
Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. | |
Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes | |
সম্পাদকীয় |